Press Releases

Press Releases

Mar 12, 2012
Summary ToggleEnzon Reports Fourth-Quarter and Full-Year 2011 Results
PISCATAWAY, NJ -- (MARKET WIRE) -- 03/12/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the fourth-quarter and full-year 2011.
Dec 8, 2011
Summary ToggleEnzon Presents Data From Phase II PEG-SN38 (EZN-2208) Study in Patients With Metastatic Breast Cancer
PISCATAWAY, NJ -- (MARKET WIRE) -- 12/08/11 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today presented data from a Phase II, open-label study in which PEG-SN38 (EZN-2208) demonstrated notable activity in patients with previously treated metastatic breast cancer.
Nov 12, 2011
Summary ToggleEnzon Presents Clinical and Preclinical Data on mRNA Antagonists at 2011 AACR-NCI-EORTC Meeting
PISCATAWAY, NJ -- (MARKET WIRE) -- 11/12/11 -- Enzon Pharmaceuticals, Inc.
Nov 3, 2011
Summary ToggleEnzon Reports 3rd Quarter 2011 Results
PISCATAWAY, NJ -- (MARKET WIRE) -- 11/03/11 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the third quarter of 2011.
Oct 17, 2011
Summary ToggleEnzon Announces Management Change, Forms Special Committee of the Board
PISCATAWAY, NJ -- (MARKET WIRE) -- 10/17/11 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced that Ana I.
Sep 22, 2011
Summary ToggleEnzon Announces Reduction in Force to Align Operations with Research and Development Activities
PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that it is implementing a plan to reduce its workforce and operating costs to more closely align its resources with the Company's research and development activities.
Aug 4, 2011
Summary ToggleEnzon Reports 2nd Quarter 2011 Results
PISCATAWAY, NJ -- (MARKET WIRE) -- 08/04/11 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the second quarter of 2011.
May 31, 2011
Summary ToggleENZON Names Ana I. Stancic Chief Financial Officer
PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that Ana I. Stancic has been named Senior Vice President and Chief Financial Officer of the Company, effective June 8, 2011 . Ms.
May 19, 2011
Summary ToggleEnzon Announces Discontinuation of PEG-SN38 Program in Metastatic Colorectal Carcinoma in Light of Evolving Standards of Care
PEG-SN38 Clinical Programs Continue in Metastatic Breast Cancer, Other Solid Tumors PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc.
May 6, 2011
Summary ToggleEnzon Reports 1st Quarter 2011 Results
--Investments in R&D translating to continued progress with oncology pipeline-- PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced its financial results for the first quarter of 2011.
Displaying 21 - 30 of 337 results